Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ruxolitinib 5 MG Clear all
Terminated Phase 2 Interventional Results available

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

NCT02120417
View directory record Official record
Conditions
Breast Cancer
Interventions
Ruxolitinib, Capecitabine, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
80
States / cities
Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 28, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT06008808
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
Interventions
Ruxolitinib, Abatacept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

NCT02119650
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma)
Interventions
Ruxolitinib, Placebo, Pemetrexed, Cisplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 28, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

NCT07424222
View directory record Official record
Conditions
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Interventions
Ruxolitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT03922724
View directory record Official record
Conditions
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Trametinib, Ruxolitinib, Retifanlimab
Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

NCT01981850
View directory record Official record
Conditions
Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
Interventions
RO7490677, Ruxolitinib
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 28, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions
EP31670
Drug
Lead sponsor
Epigenetix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

NCT00952289
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
88
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

NCT01348490
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

NCT01632904
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Ruxolitinib, Hydroxyurea (HU), HU-placebo, Ruxolitinib-placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
51
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Burbank, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01895842
View directory record Official record
Conditions
Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 28, 2026, 5:59 PM EDT
Terminated Phase 1Phase 2 Interventional

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

NCT05123040
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

NCT05622318
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab and Ruxolitinib In Solid Malignancies

NCT07219576
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Interventions
Ruxolitinib, Retifanlimab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

NCT05579769
View directory record Official record
Conditions
Hematologic Malignancy, Myeloid Malignancy
Interventions
Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

NCT06991101
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
Interventions
Ruxolitinib, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ruxolitinib in Pancreatic Cancer Patients

NCT02119663
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ruxolitinib, Placebo, Capecitabine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

NCT01375140
View directory record Official record
Conditions
Myeloproliferative Diseases
Interventions
Ruxolitinib, Lenalidomide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 28, 2026, 5:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

NCT05998408
View directory record Official record
Conditions
Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS
Interventions
Ruxolitinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT04996160
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Active, not recruiting Phase 1 Interventional

CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476
View directory record Official record
Conditions
Relapsed AML, Refractory AML
Interventions
CART123 Cells, Ruxolitinib 10 MG, Ruxolitinib 5 MG
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 28, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Ruxolitinib for Premalignant Breast Disease

NCT02928978
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 5:59 PM EDT